
Top 5 news articles of 2025
Key Takeaways
- A Drexel University researcher finds insufficient evidence connecting acetaminophen use during pregnancy to neurodevelopmental disorders.
- Medicare's negotiated drug prices, starting January 2026, offer modest discounts but may have unintended consequences for beneficiaries.
Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug sales to consumers were some of the biggest news items we covered in 2025.
Drexel University Dornsife School of Public Health researcher discusses the lack of evidence to support a link between acetaminophen use during pregnancy and neurodevelopmental disorders.
Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.
A provision in the One Big Beautiful Bill delays or exempts high-spending medications with orphan indications from Medicare drug price negotiations.
Industry leaders and policy experts have said President Trump’s executive order on Most Favored Drug Pricing is flawed and ignores the basic economics of the global drug marketplace.
Drugmakers are scrambling to set up direct-to-consumer programs in response to President Donald Trump’s executive orders. Should pharmacy benefit managers be worried? Are the programs good for patients?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.




















































